Navigation Links
Orexigen Resubmits Contrave New Drug Application
Date:12/11/2013

risk profile for Contrave; and the execution of the Contrave U.S. launch by Takeda; Orexigen's plans to seek a commercialization partner in territories outside of North America; and the timing of the submission of the CSR for the interim analysis. The inclusion of forward‐looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ materially from those expressed or implied in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: the possibility that the FDA determines not to initiate review of the Contrave NDA until it has received the CSR for the interim analysis; the SPA is not binding on the FDA if public health concerns unrecognized at the time the SPA agreement was entered into become evident, other new scientific concerns regarding product safety or efficacy arise, or if Orexigen fails to comply with the agreed upon trial protocol; the potential for the FDA to not approve Contrave even after meeting the prespecified threshold and resubmitting the NDA; the possibility that public disclosure of the results of the interim analysis would later be deemed to jeopardize the integrity of the Light Study potentially resulting in the requirement to conduct additional, costly studies; additional analysis of the interim results or new data from the continuing Light Study, including safety-related data, may produce negative or inconclusive results, or may be inconsistent with the conclusion that the interim analysis was successful; the potential that the interim analysis may not be predictive of future results in the Light Study; the potential for early termination of Orexigen's North American collaboration agreement with Takeda; the results from the interim analysis may not be sufficient to satisfy or respond to the Day 120 List of Questions from the EMA or any other data requirements of the EMA in conn
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Orexigen Therapeutics, Inc. Announces the Closing of its Offering of $115 Million of Convertible Senior Notes
2. Orexigen Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
3. Orexigen Announces Successful Interim Analysis of Contrave Light Study
4. Orexigen Therapeutics to Host Contrave Light Study Interim Analysis Conference Call and Webcast
5. Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2013
6. Orexigen and Takeda Announce Multiple Contrave Data Presentations at the ObesityWeek Meeting in Atlanta
7. Orexigen Therapeutics Enters Into Agreement with Sanofi to Manufacture Contrave for Territories Outside North America
8. A Balanced Risk-Benefit Profile Will Propel Orexigen/Takedas Contrave to Become the Most Widely Used Emerging Therapy for the Treatment of Obese and Overweight Patients
9. Orexigen Therapeutics Announces Date of Third Quarter 2013 Financial Results Conference Call and Upcoming Presentation at Credit Suisse Healthcare Conference
10. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference
11. Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 2014  CVS Health is thanking its 26,000 pharmacists ... changing the way health care is delivered to increase ... retail pharmacies, mail service pharmacies and specialty pharmacies nationwide.  ... name to CVS Health to reflect our broader health ... needed to shape the future of health," said ...
(Date:9/30/2014)... - Protecting the health and safety of Canadians is our government,s ... powers and tools at its disposal to help ensure that the ... To that end, Health Canada ... Canada of all drug products from three plants ... , Apotex Pharmachem India Pvt Ltd , Apotex Research ...
(Date:9/30/2014)... BEDFORD, Mass. , Sept. 30, 2014  Hologic, ... Stephen MacMillan , Hologic,s President and Chief Executive ... Bell Ceremony on October 1, the first day of ... will discuss the Company,s campaign focused on the important ... system approved by the FDA as clinically superior to ...
Breaking Medicine Technology:CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 2CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 3Statement by the Honourable Rona Ambrose on the import ban of drug products from three plants in India 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 3
... , Knights of Columbus partners with Medishare to provide physical therapy and prosthetic limbs ... WASHINGTON , Aug. 4 ... aid of every Haitian child who lost a limb in the January earthquake that ... Many thousands more were seriously injured, including hundreds of children who lost arms and ...
... OvaGene Oncology Inc., a biotechnology ... DNA-based diagnostics for gynecologic cancer, is pleased to announce ... the Industry Collaboration Team (ICT) program.  By becoming a ... to building a strong partnership with the GOG research ...
Cached Medicine Technology:New Program Makes Prosthetics Available to All Haitian Children Who Lost Limbs in Earthquake 2OvaGene Oncology Joins The Gynecologic Oncology Group (GOG) Industry Collaboration Team to Advance Gynecologic Cancer Research 2OvaGene Oncology Joins The Gynecologic Oncology Group (GOG) Industry Collaboration Team to Advance Gynecologic Cancer Research 3
(Date:10/2/2014)... By Dennis Thompson ... -- A newborn,s risk of developing celiac disease isn,t reduced ... found in wheat called gluten to an infant,s diet help ... a pair of new studies in the Oct. 2 ... put to rest hopes that a child could avoid celiac ...
(Date:10/2/2014)... Dennis Thompson HealthDay Reporter ... and the District of Columbia now have a total of ... that has been infecting children since the summer, U.S. ... virus have died in recent weeks, but it,s not clear ... those deaths, officials said. Health officials are also trying ...
(Date:10/1/2014)... associated with Alzheimer,s disease; however, researchers are still looking ... agent of the onset and development of the disease. ... is not harmful when found in isolation but only ... form the so-called amyloid fibrils , "We are not ... multiple ones because each aggregate of peptide, which can ...
(Date:10/1/2014)... eye, the brain of a rat and a robot ... a QUT leading robotics researcher. , Dr Michael ... new study uses new computer algorithms to enable robots ... , "This is a very Frankenstein type of project," ... a thing together because we,re taking the eyes of ...
(Date:10/1/2014)... 2014) Despite a policy focus on expanding ... this vulnerable population continues to have significant dental ... Journal of the American Dental Association , researchers ... University School of Dental Medicine report on the ... oral care provided by caregivers to adults with ...
Breaking Medicine News(10 mins):Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 2Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 3Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2Health News:Robot researcher combines nature to nurture 'superhuman' navigation 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3
... among the scientific community about whether women who are ... to shed some light on this issue, scientists from ... methods used to detect substances in breast milk, their ... in this month,s issue of the journal Analytical ...
... Andrew Lees, Professor of Neurology at University College London, is ... Memorial Medal awarded for the scientific contributions he has ... He will receive the medal following his delivery of ... Stuff," at Barts and The London Medical School on June ...
... stromal tumors (GISTs) are the most common mesenchymal ... location is less common. Nowadays, surgery is ... procedures can be performed to remove duodenal GIST. ... difficult reconstruction (like pancreaticoduodenectomy; PD). One of the ...
... increase the risk of severe asthma attacks among people with ... Medical School, Harvard Pilgrim Health Care Institute and Brigham and ... the American Thoracic Society,s journal Web site ahead of the ... Critical Care Medicine . "We found that the interaction ...
... Council for Graduate Medical Education (ACGME) task force ... presented a comprehensive set of draft standards that ... better match residents, levels of experience and emerging ... patient care in the nation,s teaching hospitals. ...
... Texas (CPRIT) has granted $3.7 million to Rice University ... The funds will help the BioScience Research Collaborative ... Bioengineering and Chemistry, in its mission to make the ... into cancer and other diseases. The work ...
Cached Medicine News:Health News:Breast milk transmits drugs and medicines to the baby 2Health News:Breast milk transmits drugs and medicines to the baby 3Health News:Lord Brain Memorial Lecture is launched in recognizing outstanding contribution to neuroscience 2Health News:Moldy homes a serious risk for severe asthma attacks in some 2Health News:ACGME task force proposes graduated duty hour and supervision standards 2Health News:ACGME task force proposes graduated duty hour and supervision standards 3Health News:ACGME task force proposes graduated duty hour and supervision standards 4Health News:ACGME task force proposes graduated duty hour and supervision standards 5Health News:Rice wins $3.7 million for cancer research 2
... PalmScan P2000 Pachymeter [i.e., PalmScan P2000] ... operated biometer, which incorporates A-mode pulsed-echo ... to accurately measure the corneal thickness ... eyes. PalmScan P2000 includes two software ...
The Cordis ANGIOGUARD® Capture Guidewire is the first embolic protection device shown in clinical testing to achieve a relative stroke reduction of 70% during carotid stenting procedures....
... hand-held, point-of-care device for the qualitative detection of ... The TOX/See device can detect up to nine ... to 8 minutes and requires only a few ... packaged to maximize convenience and ease of use. ...
... TOX/See™ is a 1-step, hand-held, point-of-care device for ... in human urine. The TOX/See device can ... abused drugs in 3 to 8 minutes and ... TOX/See cassette is individually packaged to maximize convenience ...
Medicine Products: